$-0.22 EPS Expected for Neos Therapeutics, Inc. (NEOS)

Neos Therapeutics, Inc. (NASDAQ:NEOS) Logo

Analysts expect Neos Therapeutics, Inc. (NASDAQ:NEOS) to report $-0.22 EPS on May, 9 before the open.They anticipate $0.28 EPS change or 56.00 % from last quarter’s $-0.5 EPS. After having $-0.23 EPS previously, Neos Therapeutics, Inc.’s analysts see -4.35 % EPS growth. The stock decreased 6.22% or $0.14 during the last trading session, reaching $2.11. About 178,633 shares traded. Neos Therapeutics, Inc. (NASDAQ:NEOS) has declined 73.25% since May 8, 2018 and is downtrending. It has underperformed by 77.62% the S&P500.

Neos Therapeutics, Inc. (NASDAQ:NEOS) Ratings Coverage

Among 2 analysts covering Neos Therapeutics (NASDAQ:NEOS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neos Therapeutics had 4 analyst reports since November 12, 2018 according to SRatingsIntel. The stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) earned “Market Outperform” rating by JMP Securities on Monday, November 12. As per Thursday, March 14, the company rating was maintained by Cantor Fitzgerald.

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. The company has market cap of $104.91 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It currently has negative earnings. The firm makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.

More notable recent Neos Therapeutics, Inc. (NASDAQ:NEOS) news were published by: Marketwatch.com which released: “Dow soars over 1,000 points as stocks bounce back from Christmas Eve meltdown – MarketWatch” on December 26, 2018, also Streetinsider.com with their article: “Form DEF 14A Five9, Inc. For: May 28 – StreetInsider.com” published on April 15, 2019, Seekingalpha.com published: “FDA OKs first non-drug treatment for ADHD – Seeking Alpha” on April 20, 2019. More interesting news about Neos Therapeutics, Inc. (NASDAQ:NEOS) were released by: Livetradingnews.com and their article: “Neos Therapeutics, Inc. (NASDAQ:NEOS) Value Stock at $6.50 – Live Trading News” published on June 11, 2018 as well as Seekingalpha.com‘s news article titled: “Neos Therapeutics: Buyout Target? – Seeking Alpha” with publication date: December 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.